Sugi Predict

Sugi Predict / Compounds / SCHEMBL730123

SCHEMBL730123

SCHEMBL730123

CC(C)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ LGALS1 P09382 2/20 0.37
▸ LGALS3 P17931 2/20 0.37
▸ LGALS9 O00182 1/20 0.37
▸ LGALS8 O00214 1/20 0.37
▸ PYGB P11216 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ SLC2A1 P11166 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24205780 1.00 MAPK1 (0.47) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL6037671 1.00 MAPK1 (0.47) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL7687547 1.00 MAPK1 (0.47) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL735726 1.00 MAPK1 (0.47) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL7085221 1.00 MAPK1 (0.47) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL13365613 0.94 MAPK1 (0.48) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL10388280 0.94 MAPK1 (0.48) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL16678814 0.94 MAPK1 (0.48) MAPK1ALDH1A1THRBLGALS1LGALS3
SCHEMBL21783074 0.87 MAPK1 (0.41) MAPK1ALDH1A1THRBSLC2A1
SCHEMBL24758832 0.87 MAPK1 (0.41) MAPK1ALDH1A1THRBSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4774173-A INHIBITING DE NOVO BIOMOLECULAR SYNTHESIS WITH POISONS OR ANTIBIOTICS ORGENICS LTD. (IL) 1988-09-27 — — US claimed
US-20240240175-A1 COMBINATORIAL VECTOR CLONING AND TRANSFECTION STRATEGIES FOR TARGETED INTEGRATION OF NUCLEIC ACIDS GENENTECH, INC. (US) 2024-07-18 — — US disclosed
US-11970689-B2 Cyanobacterial hosts and methods for producing chemicals UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-04-30 — — US disclosed
US-11918636-B2 Vaccine for protection against ETEC-induced diarrhea comprising dmLT SCANDINAVIAN BIOPHARMA HOLDING AB, c/o Etvax AB (SE) 2024-03-05 — — US disclosed
US-20230416759-A1 TRANSFORMANT AND METHOD FOR PRODUCING CAROTENOID COMPOSITION USING SAME EZAKI GLICO CO., LTD. (JP) 2023-12-28 — — US disclosed
EP-4245843-A1 TRANSFORMANT AND METHOD FOR PRODUCING CAROTENOID COMPOSITION USING SAME Ezaki Glico Co., Ltd. (JP) 2023-09-20 — — EP disclosed
US-20230279583-A1 RANDOMIZED CONFIGURATION TARGETED INTEGRATION OF NUCLEIC ACIDS GENENTECH, INC. (US) 2023-09-07 — — US disclosed
US-11746336-B2 Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-09-05 — — US disclosed
EP-4219682-A2 OMV VACCINES GlaxoSmithKline Biologicals SA (BE) 2023-08-02 — — EP disclosed
US-20220177605-A1 CHEMICALLY INDUCED PROTEIN DIMERIZATION SYSTEMS UNIVERSITY OF WASHINGTON 2022-06-09 — — US disclosed
EP-0404576-A2 Recombinant avipoxvirus NIPPON ZEON CO., LTD. (JP) 1990-12-27 — — EP disclosed
EP-0352763-A1 DNA fragment containing gene which encodes the function of stabilizing plasmid in host microorganism MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1990-01-31 — — EP disclosed
EP-0346187-A2 Novel GTP binding protein and method for production thereof MITSUBISHI KASEI CORPORATION (JP) 1989-12-13 — — EP disclosed
EP-0336412-A2 Synthetic oligonucleotides useful for the determination of Chlamydia trachomatis in a biological sample SCLAVO S.p.A. (IT) 1989-10-11 — — EP disclosed
EP-0329770-A1 METHOD FOR PRODUCING NOVEL POLYESTER BIOPOLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-08-30 — — EP disclosed
WO-1989000202-A2 METHOD FOR PRODUCING NOVEL POLYESTER BIOPOLYMERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-01-12 — — WO disclosed
EP-0263591-A2 Recombinant vaccinia virus DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH (JP) 1988-04-13 — — EP disclosed
WO-1987004723-A1 RECOMBINANT HUMAN B-CELL GROWTH FACTOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1987-08-13 — — WO disclosed
EP-0227938-A2 Eucaryotic fusion proteins, their preparation and use, and agents for carrying out the process HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-08 — — EP disclosed
EP-0182383-A1 Process for the preparation of oligo- and polydeoxyribonucleotides VEPEX Contractor Ltd. (HU) 1986-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177605-A1 CHEMICALLY INDUCED PROTEIN DIMERIZATION SYSTEMS BID, CNR2, RBPJ MAPK1 3295/4885ALDH1A1 4465/4885THRB 3369/4885
US-11746336-B2 Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases COASY, FASN, DHPS MAPK1 2582/4885ALDH1A1 1555/4885THRB 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.